Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
Zhang et al. JAMA Oncology 2025
Read More
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Integrating ctDNA and utDNA Across the Bladder Cancer Continuum
Watch Video
-
Inform timing on adding CTLA-4 to PD-1 monotherapy
Read More
-
Circulating tumor DNA refines risk stratification of neoadjuvant therapy- resistant breast tumors
Mark Jesus M. Magbanua, et al. Nature Communications 2025
Read More
-
From Detection to Direction: Signatera MRD testing and its impact in CRC
Watch Video
-
Understanding the IMvigor011 Study: How Signatera™ Helps Guide Bladder Cancer Treatment
Read Article
-
Using ctDNA to Inform Treatment in MIBC
Discover how personalized ctDNA testing is transforming care for patients with muscle-invasive bladder cancer (MIBC). This 30-minute webinar includes results from two landmark Phase 3 studies—IMvigor0
Watch Video
-
ctDNA Monitoring in Ovarian Cancer Patients Receiving PARPi
Toboni, Michael D, et al. Gynecologic Oncology 204 (2026)
Read More
-
Beyond the Image: New Opportunities in Gynecologic Cancer Testing
Natera hosted esteemed speakers Kathleen Moore, MD, Thomas J. Herzog, MD, and Stephanie Lheureux, MD, PhD, for an interesting discussion on the value of MRD in gynecologic oncology
Watch Video
-
Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development
Watch Video
-
Shared Decision Making Worksheet
Read More
-
Transforming Colorectal Cancer Management With Tumor-Informed MRD Testing
Read More
-
Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC
Read More
-
Facing Recurrence Again? How MRD Testing Can Support You Every Step of the Way
Read Article
-
Navigating Lung Cancer with Confidence: Making the Most of the Natera Patient Portal
Read Article
-
How MRD Testing for Recurrence and IO Therapy Provides Peace of Mind
Read Article
-
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma the rando
Long, Georgina V, et al. Nature Medicine 2025
Read More
-
Kyle’s Colon Cancer Story
Read Article
-
Optimizing Breast Cancer Surveillance: A team approach with MRD testing
Watch Video
-
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Galsky MD, Gschwend JE, Milowsky MI, et al. Ann Oncol. 2025
Read More
-
Loading More...
